Stoke Therapeutics Inc. (STOK): Price and Financial Metrics
GET POWR RATINGS... FREE!
STOK Stock Price Chart Interactive Chart >
STOK Price/Volume Stats
|Current price||$24.29||52-week high||$71.58|
|Prev. close||$23.23||52-week low||$21.42|
|Day high||$24.42||Avg. volume||154,739|
|50-day MA||$24.94||Dividend yield||N/A|
|200-day MA||$38.14||Market Cap||892.63M|
Stoke Therapeutics Inc. (STOK) Company Bio
Stoke Therapeutics, Inc. was founded in 2014 by Professor Adrian Krainer, PhD. and Isabel Aznarez, PhD to research and develop treatments for the underlying cause of genetic diseases. The company focuses on developing antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver, and kidney. Stoke’s proprietary platform, Targeted Augmentation of Nuclear Gene Output (TANGO) allows for the delivery of disease-modifying therapies in a precise and controlled manner. Edward M. Kaye, M.D., currently serves as the company’s director and Chief Executive Officer.
Most Popular Stories View All
STOK Latest News Stream
|Loading, please wait...|
STOK Latest Social Stream
View Full STOK Social Stream
Latest STOK News From Around the Web
Below are the latest news stories about Stoke Therapeutics Inc that investors may wish to consider to help them evaluate STOK as an investment opportunity.
Shares of Stoke Therapeutics (STOK) have struggled over the past 12 months, sinking by 40.8%. Year-to-date, shares are down 60.7%. However, this stock still possesses qualities that instill optimism. These, of course, have to show up somehow, and then wait for the market's verdict. Thus, I am bullish on this stock. (See Analysts’ Top Stocks on TipRanks) Based in Bedford, Massachusetts, this early-stage biopharmaceutical company is developing an RNA-based therapy for Dravet syndrome, and the autosomal dominant optic atrophy (ADOA). The first is a severe and progressive form of genetic epilepsy, while the second is the most frequent optic nerve disorder amid hereditary diseases.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS ) Bicycle Therapeutics plc (NASDAQ: BCYC ) (announced interim Phase 1 data for BT5528 and preliminary results from Phase 1 study of BT8009) Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Legend Biotech Corporation (NASDAQ: LEGN ) Click here for accessing Benzinga''s FDA Calendar Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 7) Acutus Medical, Inc. (NASDAQ: AFIB ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Amgen Inc. (NASDAQ: AMGN ) ( announced neurodegenerative disease drug...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M.D., Ph.D., will present at the Cantor Global Healthcare Virtual Conference on Tuesday, September 28, 2021, at 4:00 p.m. ET. A live audio webcast of the presentation, which will be conducted in fireside chat format, wi
Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote
Stoke Therapeutics Inc (NASDAQ: STOK) announced interim analysis data from Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome. The interim analysis is based on data from 21 patients who were treated in the single 10mg (n=5), 20mg (n=4), or 30mg (n=6) dose cohorts. A dose-proportional increase in study drug exposure was observed in plasma pharmacokinetics. Cerebrospinal fluid (CSF) exposure was measurable up to six months following a single intrathecal dose. A do
STOK Price Returns